2-(4-chlorophenyl)guanidine
2-(4-chlorophenyl)guanidine is a chemical compound with the formula C7H8ClN3. It's a derivative of guanidine, a simple organic compound with a basic functional group.
**Structure and Properties:**
* It's a white, crystalline solid.
* It has a molecular weight of 171.61 g/mol.
* The 4-chlorophenyl group is attached to the guanidine molecule at the 2-position.
**Importance in Research:**
2-(4-chlorophenyl)guanidine is an **interesting molecule for research due to its potential biological activity**. While specific research on this particular compound might be limited, its structural similarity to other guanidine derivatives suggests potential applications in:
* **Pharmacology:**
* **Anti-hypertensive activity:** Guanidine derivatives are known to have effects on blood pressure regulation. The 4-chlorophenyl group could influence the potency and selectivity of this activity.
* **Anti-inflammatory activity:** Some guanidines have shown anti-inflammatory properties. The modification with a 4-chlorophenyl group might enhance or modulate this effect.
* **Anti-cancer activity:** Guanidine derivatives are being investigated for their potential in cancer treatment. The compound's structure might influence its interaction with specific targets relevant to cancer cells.
* **Materials Science:**
* **Polymer synthesis:** Guanidines are often used as monomers for the synthesis of polymers. The 4-chlorophenyl group could provide unique properties to the resulting polymers, like enhanced stability or modified optical properties.
**Research Focus:**
To assess the true importance of 2-(4-chlorophenyl)guanidine, further research is necessary. This would involve:
* **Synthesizing and characterizing the compound:** This is crucial for understanding its physical and chemical properties.
* **Evaluating its biological activity:** This would include in vitro and in vivo studies to determine its potential effects on various biological systems.
* **Exploring its potential applications:** Further investigation might lead to the development of new drugs, materials, or other applications.
**Note:** It is important to emphasize that the importance of this compound is speculative at this point. More research is needed to confirm its actual relevance and applications.
Cross-References
ID Source | ID |
---|---|
PubMed CID | 2757788 |
CHEMBL ID | 41040 |
CHEBI ID | 103967 |
SCHEMBL ID | 1186622 |
Synonyms (53)
Synonym |
---|
HMS1784G08 |
1n-amino(immino)methyl-4-chloroaniline |
bdbm50053590 |
BRD-K39160765-003-01-1 |
n-(4-chloro-phenyl)-guanidine |
DIVK1C_006926 |
SPECTRUM_001905 |
NCGC00024592-01 |
tocris-0442 |
SPECTRUM5_001782 |
KBIO2_002434 |
KBIO2_005002 |
KBIO2_007570 , |
KBIOSS_002440 |
KBIOGR_001766 |
KBIO1_001870 |
SPECTRUM4_001243 |
SPECPLUS_000830 |
CHEMBL41040 , |
n-(4-chlorophenyl)guanidine |
4-chlorophenylguanidine |
FT-0690672 |
F2158-0389 |
CHEBI:103967 |
2-(4-chlorophenyl)guanidine |
45964-97-4 |
2-(4-chlorophenyl)guanidine;1-(4-chlorophenyl)guanidine |
A826946 |
AKOS005208040 |
1-(4-chlorophenyl)guanidine |
AB04678 |
ZSJNJAJDBNFVCA-UHFFFAOYSA-N |
n-(4-chloro-phenyl)guanidine |
SCHEMBL1186622 |
DTXSID80374034 |
p-chlorphenylguanidin |
Q27181201 |
VU0490375-1 |
mfcd00599980 |
guanidine, (4-chlorophenyl)- |
AS-30616 |
AMY27629 |
EN300-235941 |
p-chlorophenylguanidine |
CS-0452657 |
PD071245 |
chlorhexidine diacetate impurity e [ep impurity] |
n-p-chlorophenylguanidine |
n-4-chlorophenylguanidine |
guanidine, (p-chlorophenyl)- |
chlorhexidine digluconate solution impurity e [ep impurity] |
guanidine, n-(4-chlorophenyl)- |
3QJ5KU64Y3 |
Drug Classes (1)
Class | Description |
---|---|
organochlorine compound | An organochlorine compound is a compound containing at least one carbon-chlorine bond. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (15)
Potency Measurements
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 1.0000 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
TDP1 protein | Homo sapiens (human) | Potency | 24.3464 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 31.6228 | 0.0020 | 7.5337 | 39.8107 | AID891 |
cytochrome P450 2C19 precursor | Homo sapiens (human) | Potency | 39.8107 | 0.0025 | 5.8400 | 31.6228 | AID899 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Inhibition Measurements
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
5-hydroxytryptamine receptor 3E | Homo sapiens (human) | Ki | 0.3220 | 0.0010 | 0.8835 | 9.9000 | AID6339; AID6343 |
Solute carrier family 22 member 2 | Homo sapiens (human) | IC50 (µMol) | 18.9000 | 0.4000 | 3.1000 | 9.7000 | AID1463535 |
Solute carrier family 22 member 1 | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.2100 | 5.5537 | 10.0000 | AID1463534 |
Solute carrier family 22 member 3 | Homo sapiens (human) | IC50 (µMol) | 2.8000 | 0.0900 | 3.7277 | 9.5000 | AID1463536 |
5-hydroxytryptamine receptor 3B | Homo sapiens (human) | Ki | 0.3220 | 0.0010 | 0.8711 | 9.9000 | AID6339; AID6343 |
Plasminogen | Homo sapiens (human) | Ki | 5,025.0000 | 0.0170 | 1.1560 | 4.4000 | AID157969; AID157989 |
Urokinase-type plasminogen activator | Homo sapiens (human) | Ki | 6.3843 | 0.0170 | 2.6268 | 7.0000 | AID215831; AID215841; AID215976 |
Cationic trypsin | Bos taurus (cattle) | Ki | 119.9750 | 0.0000 | 1.0753 | 9.0000 | AID215213; AID215237 |
5-hydroxytryptamine receptor 3A | Homo sapiens (human) | Ki | 0.3220 | 0.0000 | 0.7411 | 9.9000 | AID6339; AID6343 |
5-hydroxytryptamine receptor 3D | Homo sapiens (human) | Ki | 0.3220 | 0.0010 | 0.8835 | 9.9000 | AID6339; AID6343 |
5-hydroxytryptamine receptor 3C | Homo sapiens (human) | Ki | 0.3220 | 0.0010 | 0.8835 | 9.9000 | AID6339; AID6343 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Biological Processes (92)
Molecular Functions (42)
Ceullar Components (33)
Bioassays (25)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
AID95039 | Inhibition against human plasma Kallikrein at 2 mM | 1990 | Journal of medicinal chemistry, Nov, Volume: 33, Issue:11 | Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses. |
AID215237 | log1/Ki value was calculated against Trypsin | 1990 | Journal of medicinal chemistry, Nov, Volume: 33, Issue:11 | Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses. |
AID1463539 | Selectivity ratio of IC50 for human OCT1 expressed in HEK293 cells to IC50 for human OCT3 expressed in HEK293 cells | 2017 | Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18 | A new chemotype inhibitor for the human organic cation transporter 3 (hOCT3). |
AID1463540 | Competitive inhibition of human OCT3 expressed in HEK293 cells up to 25 uM in presence of varying concentration of MPP+ by Lineweaver-Burk plot analysis | 2017 | Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18 | A new chemotype inhibitor for the human organic cation transporter 3 (hOCT3). |
AID210572 | Inhibition against Tissue plasminogen activator at 1 mM | 1990 | Journal of medicinal chemistry, Nov, Volume: 33, Issue:11 | Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses. |
AID215831 | In vitro inhibition of HWMT human urokinase Plasminogen activator. | 2002 | Bioorganic & medicinal chemistry letters, Jan-21, Volume: 12, Issue:2 | Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 1: 2-Pyridinylguanidines. |
AID157969 | Ability to inhibit human plasmin using Chromozym-PL as substrate | 2002 | Bioorganic & medicinal chemistry letters, Jan-21, Volume: 12, Issue:2 | Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 1: 2-Pyridinylguanidines. |
AID215841 | Inhibition against Urokinase-type plasminogen activator | 1990 | Journal of medicinal chemistry, Nov, Volume: 33, Issue:11 | Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses. |
AID1463535 | Inhibition of human OCT2 expressed in HEK293 cells assessed as decrease in uptake of substrate [3H]MPP+ after 1 min by liquid scintillation counting method | 2017 | Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18 | A new chemotype inhibitor for the human organic cation transporter 3 (hOCT3). |
AID1463537 | Selectivity ratio of IC50 for human OCT2 expressed in HEK293 cells to IC50 for human OCT3 expressed in HEK293 cells | 2017 | Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18 | A new chemotype inhibitor for the human organic cation transporter 3 (hOCT3). |
AID210743 | Ability to inhibit human tissue plasminogen activator stimulator at concentration of 1 mM | 2002 | Bioorganic & medicinal chemistry letters, Jan-21, Volume: 12, Issue:2 | Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 1: 2-Pyridinylguanidines. |
AID1463536 | Inhibition of human OCT3 expressed in HEK293 cells assessed as decrease in uptake of substrate [3H]MPP+ after 1 min by liquid scintillation counting method | 2017 | Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18 | A new chemotype inhibitor for the human organic cation transporter 3 (hOCT3). |
AID1463534 | Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of substrate [3H]MPP+ after 1 min by liquid scintillation counting method | 2017 | Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18 | A new chemotype inhibitor for the human organic cation transporter 3 (hOCT3). |
AID210841 | Inhibition against human plasma thrombin at 1.0 mM | 1990 | Journal of medicinal chemistry, Nov, Volume: 33, Issue:11 | Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses. |
AID6343 | Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20 | Structure-activity relationships for the binding of arylpiperazines and arylbiguanides at 5-HT3 serotonin receptors. |
AID215213 | Inhibition against Trypsin | 1990 | Journal of medicinal chemistry, Nov, Volume: 33, Issue:11 | Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses. |
AID215976 | log1/Ki value was calculated against Urokinase-type plasminogen activator | 1990 | Journal of medicinal chemistry, Nov, Volume: 33, Issue:11 | Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses. |
AID6339 | Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand. | 2001 | Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12 | The binding of arylguanidines at 5-HT(3) serotonin receptors: a structure-affinity investigation. |
AID157989 | Inhibition against human plasmin was determined at 0.5 mM | 1990 | Journal of medicinal chemistry, Nov, Volume: 33, Issue:11 | Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses. |
AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
AID493017 | Wombat Data for BeliefDocking | 2002 | Bioorganic & medicinal chemistry letters, Jan-21, Volume: 12, Issue:2 | Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 1: 2-Pyridinylguanidines. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (10)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (20.00) | 18.2507 |
2000's | 2 (20.00) | 29.6817 |
2010's | 4 (40.00) | 24.3611 |
2020's | 2 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.34
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.34) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |